Latest media releases

Corporations, clients and friends of UBS rally to support the UBS SARS Research Foundation

Media Releases APAC

UBS, in cooperation with the Faculty of Medicine at the University of Hong Kong ("HKU"), today announced that donations to the UBS SARS Research Foundation from corporate and individual donors has exceeded HK$2.5 million.

The donations from corporate and individual donors augment the HK$1 million of seed capital provided by UBS, UBS employee donations and UBS's matched-giving programme of up to HK1 million to match employee contributions.

The Foundation, launched on 11th June this year, has the primary objective of raising money to fund SARS-related research spearheaded by the Medical Faculty. Proceeds will be used to develop high throughput diagnostic tests, anti-viral treatments and eventually, it is hoped, a vaccine for SARS.

A HK$500, 000 donation by the DH Chen Foundation was the largest single corporate donation. Other major benefactors include the Fortune Pharmacal Co, the KK Ho International Charitable Foundation, the SH Ho Foundation, Edward Wong & Co, Yanlord Investment PTE and the Chan Kwan Biu Memorial Foundation.

The Airport Authority Hong Kong made a significant donation comprising the proceeds of the sale of unclaimed items from its Lost & Found Department.

"From the beginning it was our hope that the UBS SARS Research Foundation would provide a vehicle for groups and individuals, other than UBS and its employees, to support the important work being undertaken by scientists at HKU. The response from the corporations - and their employees, individual clients of UBS and other friends of the firm has been wonderful. The Foundation was established in the belief that SARS was a global problem and the response from donors outside Hong Kong has vindicated this belief," said Kathryn SHIH, Chief Executive of UBS Hong Kong Branch.

"Though SARS seems to be under control for the time being, a great deal remains to be discovered about this new disease. The University of Hong Kong has embarked on a continuous programme to identify better diagnostic tools, to look for a more effective therapy, and to develop vaccines for ultimate prevention of this deadly disease. The generous contributions from the community to the UBS SARS Research Foundation are providing invaluable support to the research team at the University of Hong Kong in its battle against the SARS virus," said Professor LAM Shiu-Kum, Dean of the Faculty of Medicine.

Hong Kong, 18 July 2003